Venus Remedies Limited has announced that it has received market authorizations for Paclitaxel 100m9/16.7rn1 and Zolendronic Acid 4mg in the Philippines, located in the dynamic region of Asia (South East).

In addition, the company has also secured market authorization for Bleomycin 1SlU from Saudi Arabia. These regulatory approvals signify a significant milestone for Venus Remedies Limited, reflecting the company's commitment to advancing healthcare solutions and expanding its global presence. The company is dedicated to delivering high-quality pharmaceuticals that contribute to improving patient outcomes and addressing critical medical needs.